<DOC>
	<DOC>NCT01254448</DOC>
	<brief_summary>This is a Phase 1 study to examine the safety, tolerability and pharmacokinetics of TC-5619 in elderly subjects with and without Alzheimer's disease. Group 1 includes elderly subjects with Alzheimer's disease to receive TC-5619 or placebo for 28 days to evaluate safety and tolerability. Group 2 includes healthy elderly subjects in a dose escalation design to receive TC-5619 or placebo for 10 days to evaluate safety, tolerability and pharmacokinetics.</brief_summary>
	<brief_title>Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria (Groups 1 &amp; 2): Normal body mass index (BMI) Nonsmoking for a minimum of 3 months Subjects must be in reasonably good health, based on medical history, physical examination, vital signs, and ECG. Group 1 Only: Subjects a Mini Mental State Examination score between 1222, inclusive. Diagnosis of probable Alzheimer's Disease according to National Institute of Neurological and Communicative Disorders and StrokeAlzheimer's Disease and Related Disorders Association (NINCDSADRDA) criteria Subjects must have a reliable caregiver. Exclusion Criteria (Groups 1 &amp; 2): Subjects with clinically significant heart disease, pulmonary disease, diabetes, neurologic or psychiatric disease (Group 1 subjects must have Alzheimer's Disease), or any other illness that could interfere with interpretation of study results. Subjects with a past or current history of seizures cannot participate. Current use of donepezil, rivastigmine or galantamine.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Alzheimer's Disease</keyword>
</DOC>